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Abstract
Diseases transmitted by mosquitoes have a devastating impact on global health and this is worsening due to difficulties
with existing control measures and climate change. Genetically modified mosquitoes that are refractory to disease
transmission are seen as having great potential in the delivery of novel control strategies. Historically the genetic
modification of insects has relied upon transposable elements which have many limitations despite their successful use. To
circumvent these limitations the Streptomyces phage phiC31 integrase system has been successfully adapted for site-
specific transgene integration in insects. Here, we present the first site-specific transformation of Anopheles gambiae, the
principal vector of human malaria. Mosquitoes were initially engineered to incorporate the phiC31 targeting site at a
defined genomic location. A second phase of genetic modification then achieved site-specific integration of Vida3, a
synthetic anti-malarial gene. Expression of Vida3, specifically in the midgut of bloodfed females, offered consistent and
significant protection against Plasmodium yoelii nigeriensis, reducing average parasite intensity by 85%. Similar protection
was observed against Plasmodium falciparum in some experiments, although protection was inconsistent. In the fight
against malaria, it is imperative to establish a broad repertoire of both anti-malarial effector genes and tissue-specific
promoters for their expression, enabling those offering maximum effect with minimum fitness cost to be identified. In the
future, this technology will allow effective comparisons and informed choices to be made, potentially leading to complete
transmission blockade.
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Introduction
Despite intense efforts, malaria is responsible for almost one
million deaths per year, predominantly in sub-Saharan Africa [1].
As a result of intervention, the mosquito vectors are increasingly
resistant to pesticides [2] and the causative Plasmodium parasites are
becoming resistant to widely used anti-malarial drugs [3]. In the
absence of an effective vaccine, alternative strategies are badly
needed. Control measures that focus on the vector remain the
most effective and the deployment of transgenic mosquitoes,
refractory to malaria transmission, is increasingly seen as having
great potential [4]. In fact, some success has recently been
reported in Anopheles stephensi [5]. The focus of this study is Anopheles
gambiae, the major malaria vector in endemic regions of sub-
Saharan Africa.
Insect transgenesis has relied upon transposable genetic
elements which, despite their utility, have limited carrying capacity
and their essentially random integration can cause insertional
mutagenesis and position effects [6,7]. The Streptomyces phiC31 site-
specific transgene integration system circumvents these problems
[8,9] and can potentially accept much larger inserts than the 42 kb
Streptomyces phage genome [10]. Site-specificity results from the two
phase nature of the system. In phase 1, the phage attachment site
(attP) is integrated into the genome using conventional transposon-
mediated transgenesis. During phase 2 transformation, catalysed
by integrase, the attP site accepts transgenes from plasmids
containing the bacterial attachment site (attB). Integration
recombines attP and attB sites into unique attL and attR sequences
that are not recognised by the integrase, rendering insertions
unidirectional and stable.
Adaptation of the phiC31 integration system for Drosophila
melanogaster was successful [11] and we subsequently reported its
use in the yellow fever and dengue virus vector, Aedes aegypti [9].
Here we report the first site-specific transformation of An. gambiae
and its use to express a synthetic, anti-malarial effector gene,
Vida3 [12], into the midgut lumen following a bloodmeal. The 14
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effective against complex outer membranes, was active against
both early sporogonic stages and developing oocysts of murine
malaria parasites in An. gambiae infections in vivo [12].
The results presented here demonstrate stable expression of Vida3
over a number of generations, which significantly reduced the
intensity of Plasmodium yoelii nigeriensis infections. Whilst protection
against the human parasite, Plasmodium falciparum, was inconsistent, a
significant reduction in oocyst burden was observed under certain
conditions. The expression of peptides screened against the human
parasite, combined with site-specific transgene integration to allow
direct comparisons to be made between potential effector genes, will
provide valuable advances in the fight against malaria.
Results
Generation and characterisation of attP targeting strains
Four independent An. gambiae targeting strains for phiC31
integrase were generated by piggyBac-mediated integration of the
attP target site, linked to an eye-specific ECFP marker. In total,
2311 wild-type KIL strain embryos were injected with the phase 1
plasmid, pBac[3xP3-ECFPaf]-attP (Figure 1A) [9]. Surviving G0
adults were backcrossed to KIL and a number of G1 transformants
identified. Four independent strains (C, E, G and H) were
identified by unique patterns of ECFP expression in neural tissue
(optic nerve, cerebral ganglia, ventral nerve ganglia and anal
papillae), in addition to eye expression (Figure 1B).
Populations of targeting strains were established from single G1
positive adults by backcrossing to wild-type. Southern blot analysis
identified single insertions in str a i n sE ,Ga n dHa n dt w oi n s e r t si n
strain C (Figure 1C). For each strain, sequence flanking one side of the
genomic integration site was obtained from inverse PCR products.
AlignmentofsequencestothePESTgenomeusingtheBlastalgorithm
[13] allowed the other flanking sequence to be confirmed by genomic
PCR using one primer within the transgene and a second designed to
the adjacent PEST genome. All showed canonical piggyBac TTAA
sequence duplication (Table S1), although the second integration site
in strain C could not be resolved. The identified integration sites were
mapped to chromosomes 3R (strains C and E) and 2L (strains G and
H). The strain C insertion was located 2.5 kb from a predicted gene,
whilst those for strains E, G and H were all more than 15 kb from
predicted genes. Backcrosses confirmed normal Mendelian inheri-
tance of the fluorescent marker in strains E, G and H (Table S2). No
obviousfitnessdisturbanceswereapparentforanyofthestrainsduring
normal husbandry and strain E was chosen for site-specific integration
following enrichment for the targeting site.
Figure 1. Generation and genomic analysis of attP targeting
strains. (A) Transgene organisation of the piggyBac insertion from
pBac[3xP3-ECFPaf]-attP (not to scale) showing an unoccupied attP
target site, ECFP marker controlled by the D. melanogaster 3xP3 eye-
specific promoter and piggyBac left and right terminal inverted repeats
(pB-L and pB-R). The double headed arrow identifies the probe used in
Southern blot analysis, excised using EcoRV and PstI sites, and single
arrows the location of PCR primers to amplify a 391 bp fragment
spanning attP. (B) Fluorescence profiles of transgenic strain E, G and H
larvae. For all strains: i, dorsal bright-field image; ii, dorsal ECFP image;
iii, ventral bright-field image; iv, ventral ECFP image. In addition to eyes
and optic nerves (all strains), fluorescence is visible in cerebral ganglia
and anal papillae (strains E and H) and ventral nerve ganglia (strain H).
(C) Southern blot analysis of phase 1 targeting strains E, G, H and C.
Genomic DNA is either uncut (1) or digested with XmnI (2), NsiI (3) or
PstI (4) and probed with the 2195 bp EcoRV/PstI fragment described
above. The band generated following NsiI digestion of strain C genomic
DNA most likely represents a doublet.
doi:10.1371/journal.pone.0014587.g001
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site-specific integration
Vida3, a synthetic anti-Plasmodium peptide [12], was chosen for
expression in phase 2. The expression strategy previously used for the
SM1 peptide was adopted to target early ookinetes in the ingested
bloodmeal and ensure release of the very small peptide from
ribosomes [14]. Vida3 was thus expressed as a tetramer using the
An. gambiae carboxypeptidase (AgCP) promoter, signal peptide and
untranslated regions (Figure 2A). In addition to an attB sequence, the
phase 2 plasmid included an eye-specific DsRed2 fluorescence
marker.
Phase 2 injections into 6124 strain E embryos generated two
phase 2 transgenic larvae, one of which emerged as an adult male.
The resulting EVida3 strain was identified by the expression of both
ECFP and DsRed2 fluorescence (Figure 2B). Correct site-specific
integration was confirmed by PCR across the resulting attL and attR
regions in EVida3 (Figure 2C) and the sequence of cloned products
confirmed. A backcross to wild-type confirmed normal Mendelian
inheritance of both fluorescent markers in EVida3 (Table S2).
Semi-quantitative RT-PCR, on total RNA extracted from
EVida3 females at different times post-bloodmeal, was used to
determine the expression profile of the Vida3 tetramer from the
AgCP promoter (Figure 3A). Intensity of PCR products, normalised
to ribosomal protein L7a (rpL7a), showed upregulation from basal
levels following a bloodmeal and peak expression after 6 hours. By
48 hours post-bloodmeal, mRNA abundance had returned to
normal, thus expression is consistent with that reported for SM1
[14] and endogenous AgCP [15]. We confirmed exclusive
expression of Vida3 in the midgut by RT-PCR on midgut and
carcass 6 hours post-bloodmeal (Figure 3B). Vida3 expression in
EVida3 has been stable for over 40 generations (data not shown).
Infection challenge with Plasmodium yoelii nigeriensis
We observed no significant difference in female wing length, an
accepted measure of body size, between strain E and EVida3
homozygotes (P=0.127). Thus, we could infer that females from
each strain would take similar sized bloodmeals during infection
experiments. To test Vida3 activity against parasites, we first
infected strains E and EVida3 with the murine parasite Plasmodium
yoelii nigeriensis. Midgut infections were counted as a measure of
intensity and prevalence. In addition to oocysts we frequently
observed melanised ookinetes and, since these had traversed the
midgut epithelium, they were included as invading parasites. Five
independent infections were performed over two years (Table 1).
Intensity of infection with P. y. nigeriensis was significantly reduced
in EVida3, compared to E, in all five experiments. Since levels of
infection varied considerably between experiments, data are
shown as separate boxplots for independent experiments and the
pooled data (Figure 4A) and as a composite plot in Figure S1.
Experiments 1 to 5 resulted in decreased mean parasite burdens in
EVida3 compared to E of 83%, 77%, 80%, 87% and 67%
respectively. When the data from all five experiments are pooled,
this reduction is very highly significant (P,0.0001). Although
parasite burden varies significantly between experiments
(P,0.0001) this interaction is not significant (P=0.3). Prevalence
of infection was also reduced in EVida3, although this reduction
was only significant in experiment 2 (P=0.02, Figure 4B).
Infection challenge with Plasmodium falciparum
To assess the impact of Vida3 on human parasites, E and
EVida3 homozygotes were fed in vitro cultured P. falciparum
gametocytes, in eight independent experiments, over a two year
period (Table 2). Oocyst burden in independent experiments was
Figure 2. Genome organisation and characterisation of phase 2
site-specific integrations. (A) Organisation of the occupied target site
(not to scale) following site-specific integration of pBattB-DsRed2-AgCP-
vida tet and resolution of attB and attP into attL and attR. The insertion is
flanked by phase 1-specific left and right piggyBac terminal inverted
repeats (pB-L and pB-R) and the ECFP fluorescent marker. Vida3 is
expressed from the An. gambiae carboxypeptidase (AgCP) promoter and
marked by 3xP3:DsRed2. The transcribed region (expanded) includes the
AgCP 59 and 39 UTRs (light grey narrow boxes) and signal peptide (light
grey wider box) and four copies of Vida3 (dark grey boxes), separated by
linker sequences (white boxes). Arrows identify PCR primers that amplify
fragments specific to attL and attR. (B) Fluorescence profiles of EVida3
phase 2 larvae; i, dorsal bright-field image; ii, dorsal ECFP image; iii, dorsal
DsRed2 image; iv, ventral bright-field image; v, ventral ECFP image; vi,
ventral DsRed2 image. In addition to eyes and optic nerves fluorescence
is visible in cerebral ganglia, anal papillae and ventral nerve ganglia.
Following integration in phase 2, strain E exhibits fluorescence in ventral
nerve ganglia, which was not clearly visible in phase 1. This may reflect
some degree of cross-talk between the two filter sets given the high
intensity of the red fluorophore. Note also that DsRed2 expression is
restricted to the cell nuclei by a nuclear localisation signal. (C)
Confirmation of site-specific transgene integration in EVida3. PCR
reactions with no template, strain E DNA or strain EVida3 DNA were
established with specific primers for attL (301 bp, lanes 1, 2 and 3), attR
(224 bp, lanes 4, 5 and 6) or attP (391 bp, lanes 7, 8 and 9).
doi:10.1371/journal.pone.0014587.g002
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intensity in EVida3 compared to E was observed in experiments 2,
7 and 8 (P,0.0001 for all). In experiments 4 and 5, where control
infections were lower, a significant increase in oocyst burden was
observed in EVida3 (P,0.0001 and P=0.0002 respectively).
Analysis of the pooled data, which indicates a reduced burden in
EVida3, does not show a significant difference to E (P=0.13),
although experiments are significantly different (P,0.0001), and
have a significant interaction (P,0.0001). Since P. falciparum
experimental infections are inherently variable, the oocyst burden
was also analysed after excluding uninfected mosquitoes. Results
were indicative of a reduced oocyst burden in EVida3 but
statistically inconclusive (P=0.05). For experiments 6 to 8, a
second uninfected bloodmeal was given after three days to increase
infections [16]. Analysis of pooled data from these experiments did
identify a significant reduction in oocyst burden for EVida3
(P,0.0001), although variation between experiments remains a
significant interaction (P,0.0001). Overall, when infections were
high, expression of Vida3 did offer a significant level of protection.
The prevalence of infection for pooled data showed no significant
difference between E and EVida3, although differences were
observed in individual experiments (Figure 5B). Prevalence in
EVida3 was significantly reduced in experiments 2 (P=0.011) and
3( P=0.025) but significantly increased in experiment 4
(P=0.0003).
Discussion
In this study we have demonstrated the utility of Streptomyces
phiC31 site-specific transgene integration as a tool that will help
advance research capability in An. gambiae. We previously
published the establishment of the phiC31 system in Ae. aegypti
and demonstrated increased efficiency compared to traditional
transposon-mediated transgenesis [9]. Results published here,
following the integration of a single phase 2 plasmid, demonstrate
a proof of principle, but not an increased efficiency for site-specific
integration for this particular construct. For site-specific integra-
tion, our experience with Ae. aegypti would indicate that size, along
with other unknown characteristics of phase 2 plasmids, have a
direct bearing on integration success. An inverse correlation
between the size of phase 2 plasmids and transformation efficiency
was also reported for site-specific integration in D. melanogaster [10].
The Vida3 phase 2 plasmid used here is significantly larger than
the minimal plasmid used in the previous study (7.2 kb compared
to 4.6 kb) [9] and the impact of expressing an effector gene is also
unknown. The low efficiency reported in this study is therefore
most likely due to characteristics of the phase 2 plasmid used, a
hypothesis confirmed by reports of efficient integrations into our
targeting strain E in unrelated projects (Nolan, pers. comm.). These
workers injected 1571 strain E embryos to generate three
independent phase 2 lines, with an estimated transformation
efficiency of 10%.
Several modifications could enhance efficiency of the system in
the future. Driver lines, expressing an endogenous source of
integrase in the embryo from either nanos or vasa gene regulatory
elements, were shown to double the transformation efficiency in D.
Figure 3. Expression of Vida3 from the AgCP promoter. (A)
Expression of Vida3 in strain EVida3 following a bloodmeal. (i)
Representative gels showing semi-quantitative RT-PCR products of
rpL7a (15 cycles, upper panel) and Vida3 (25 cycles, lower panel) from
samples taken at 0, 1.5, 3, 6, 12, 24 and 48 hours post-bloodmeal. (ii)
Mean relative intensity with standard errors of Vida3 PCR products.
Following quantification, Vida3 RT-PCR bands were normalised to
ribosomal protein rpL7a RT-PCR products from the same samples and
expressed relative to the 0 time point. The histogram represents data
from a minimum of two replicates. (B) RT-PCR of Vida3 expression in the
midgut and carcass 6 hours post blood-meal.
doi:10.1371/journal.pone.0014587.g003
Table 1. P. y. nigeriensis infections of transgenic strains E and
EVida3.
parasitaemia
(exflagellation) strain n median
interquartile
range
1 7% E 34 10.5 1–34.5
(3) EVida3 49 2 0–9
2 4% E 33 2 1–4.5
(1.7) EVida3 36 1 0–1
3 8% E 26 23 1.5–95.8
(3) EVida3 40 3 0–14.8
4 8% E 44 24.5 6.25–72.75
(1.9) EVida3 56 3 1–13.5
5 9% E 52 66 41.5–119.25
(0.8) EVida3 50 21.5 2.75–49.25
1–5 E 189 20 2–72.5
EVida3 231 3 0–14
Details of mouse infections (parasitaemia and exflagellation), numbers of
mosquitoes dissected (n), median and inter-quartile range of intensity of
infections for experiments 1 to 5 and the pooled data.
doi:10.1371/journal.pone.0014587.t001
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mRNA [17]. These genes have now been characterised in An.
gambiae [18,19] facilitating the transfer of this improved technology
to mosquitoes. However, An. gambiae is known to be difficult to
transform, highlighted by the scarcity of publications [20–24], and
efficiencies are unlikely to reach the levels reported for D.
melanogaster or Ae. aegypti. Techniques have also been established
for stabilisation of the initial piggyBac insertions by removal of one
or both termini [25–27] should potential re-mobilisation be seen as
an issue with respect to either phenotypic stability or regulatory
approval. In the most recent study [27] a three-step integration
and stabilisation system was designed using the phiC31 system in
the Mediterranean fruit fly, Ceratitis capitata.
Comprehensive fitness studies involving strains E and EVida3,
such as those published for An. stephensi [28], are ongoing and will
be important for determining the likely effectiveness of such strains
for potential field release. Initial studies reported here demonstrate
that both fluorescent markers show normal Mendelian inheritance
and that expression of the effector gene does not have a significant
impact on wing length or development during normal husbandry.
Infection experiments with P. y. nigeriensis were consistent
between replicates spanning two years, despite different levels of
infection. Expression of Vida3 resulted in a significant reduction in
parasite intensity compared to controls. The mean reduction in
parasite burden of 79% in EVida3 is consistent with the 80%
reduction in intensity previously published for the action of the
peptide on P. y. nigeriensis during in vitro experiments [12]. A
significant reduction in the prevalence of infection was also
observed in the pooled data.
In contrast, the infection of transgenic mosquitoes with in vitro
cultured P. falciparum gametocytes was more challenging. This is
reflected in different relative infection rates between the two strains
and inconsistency between experiments. Overall, the data suggest
a trend towards reduced parasite intensity in EVida3 but no
consistent significant differences between either the prevalence or
intensity of infection in EVida3 compared to E. However, there is
existing published evidence for an increase in P. yoelii infections in
An. stephensi mosquitoes given a second uninfected bloodmeal [16]
and where mosquitoes were given a subsequent bloodmeal in
experiments 6 to 8, an overall significant reduction in EVida3
oocyst burden was observed. These experiments, involving
multiple bloodmeals, more closely mimic the situation in the field,
but conditions in the laboratory are optimised for high infections
which are atypical. In addition to providing additional resources,
the subsequent bloodmeal would initiate a second burst of Vida3
expression. Although we would not normally expect peptides
Figure 4. Parasite intensity and prevalence following P. y.
nigeriensis infections of transgenic strains E and EVida3. (A)
Boxplots show intensity for strains E (white boxes) and EVida3 (grey
boxes) from five independent experiments and the pooled data.
Oocysts and melanised ookinetes were scored as invading parasites.
Vertical lines denote the 95% confidence interval, horizontal lines with
symbol mark the median and the interquartile range of the data is
boxed. Probabilities for significant reductions in intensity in EVida3 (*) in
experiments are: 1, P=0.008; 2, P=0.0007; 3, P=0.009; 4, P,0.0001; 5,
P,0.0001 and pooled data 1–5, P,0.0001. (B) Histograms show
prevalence for strains E (white bars) and EVida3 (grey bars) in
experiments 1–5 and the pooled data. Results from individual
experiments indicate a trend towards a lower prevalence of infection
in EVida3, which is only significant (*) for experiment 2 (P=0.02) and the
pooled data 1–5 (P,0.001).
doi:10.1371/journal.pone.0014587.g004
Table 2. Infection data for P. falciparum infections of strains E
and EVida3.
gametocytes
(male ratio) strain n median
interquartile
range
1 3.2610
7 E 30 6.5 0.75–20
(0.58) EVida3 30 7 2–18.5
2 2.6610
7 E 30 26.5 10.5–44.25
(0.60) EVida3 30 3 0.75–10.75
3 1.9610
7 E 30 5 2–19.75
(0.55) EVida3 33 3 1–17.5
4 1.7610
7 E3 0 10 – 5
(0.77) EVida3 30 8.5 5.75–13
5 2.3610
7 E 30 2 0.75–4.25
(0.49) EVida3 30 10 3.75–20
6 4.9610
7 E 30 11.5 2–32.5
(0.56) EVida3 30 20 10.25–41.5
7 3.3610
7 E 30 50 28–100.25
(0.52) EVida3 30 7.5 3–27.5
8 2.4610
7 E 30 101.5 77.25–122.75
(0.60) EVida3 30 26.5 8.5–66.5
Details of gametocyte infections, male ratio, numbers of mosquitoes dissected
(n), median and inter-quartile range of intensity of infections for experiments 1
to 8.
doi:10.1371/journal.pone.0014587.t002
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developing beneath the midgut basal lamina, the Vida3 monomer
presumably accessed this immune privileged site from the
haemolymph in experiments where P. berghei oocyst numbers were
significantly reduced following injection of Vida3 into the
haemocoel [12]. The effect of Vida3 expression on P. falciparum
does however appear to depend upon infection rates. We observed
a significant decrease in intensity in EVida3 when control
infections were high (experiments 2, 7, 8) and significant increases
when control infections were low (experiments 4, 5). This is
consistent with an earlier study where Yoshida et. al. [29] observed
greater variation in the reduction of P. falciparum infections
compared to murine parasites in transgenic An. stephensi expressing
haemolytic C-type lectin into the midgut. Here too a significant
reduction was only observed in the experiment where control
infections were high. The reasons for this are unclear. Since An.
gambiae is a natural host for P. falciparum, we postulate that
infections are kept low by a robust and effective immune response
[30]. If initial infections were high in experiments 4 and 5, an
elevated immune response could be expected in strain E. A
reduction in ookinete numbers by Vida3 would potentially result
in reduced immune stimulation, causing resulting infections to be
higher in EVida3 than E. Experiment 4 was also the only
experiment where prevalence of infection was significantly
increased in EVida3. A recent study of in vitro cultured P. falciparum
infections reported higher parasite transmission success with
increasing male sex ratios at low gametocyte densities [31].
Interestingly, the male gametocyte ratio was highest in experiment
4 (0.77 compared to 0.52 – 0.6 in the other seven experiments,
Table 2) and gametocyte density was lowest (1.7610
7/ml,
compared to 1.9 – 4.9610
7/ml in the other seven experiments),
conditions which could favour an initially high infection in this
particular experiment.
Some components of the mosquito immune response are
expressed in a dose dependant manner following Plasmodium
infection [32]. In addition, parasite developmental transitions
within the mosquito are density-dependant [33]. Since P. y.
nigeriensis but not P. falciparum parasites were melanised in this
study, it is likely that An. gambiae mounts different immune
responses, as is seen with P. berghei and P. falciparum infections
[30,34,35]. These studies also identified parasite species-specific
components of the mosquito immune response. The consequences
of Vida3 expression on immune responses initiated by different
parasites are therefore likely to be complex and highlight the
importance of relevant parasite/vector choices in the future.
This study is the first report of site-specific effector gene
integration and expression in An. gambiae and represents a
significant step forward in malaria research. Vida3 consistently
and significantly reduced infections of the mouse parasites against
which it was originally screened, but showed inconsistent results
against human malaria parasites. We are confident that ongoing
work to identify peptides more active against P. falciparum will allow
mosquitoes with significantly reduced transmission of human
malaria to be generated in the near future. With this in mind, our
phase 2 plasmid is modular, and designed to accept different
effector genes. Moreover site-specific integration facilitates direct
comparisons between alternative anti-malarial effector molecules
and promoters. Ultimately the incorporation of multiple effector
genes, expressed into combinations of midgut, haemocoel and
salivary glands will become feasible. This is likely to be the way
forward for complete transmission blockade.
Materials and Methods
Plasmids
pBac[3xP3-ECFPaf]-attP has been described previously [9].
The phase 2 transformation construct pBattB-DsRed2-AgCP-vida
contains a 269 bp fragment flanked by BamHI restriction sites and
comprising four repeats of the Vida3 coding sequence ([Vida3]4),
each separated by a flexible linker. This fragment was made by
annealing two pairs of oligonucleotides (VTET 1 FOR with
VTET 1 REV and VTET 2 FOR with VTET 2 REV). Annealed
oligos were phosphorylated and ligated using the 4 bp overhang.
Codon usage for the Vida 3 repeats in each fragment was different,
to help prevent misalignment of the oligos during annealing. The
Figure 5. Parasite intensity and prevalence following P.
falciparum infections of transgenic strains E and EVida3. (A)
Boxplots show parasite intensity for strains E (white boxes) and EVida3
(grey boxes) from 8 independent experiments. Vertical lines denote the
95% confidence interval, horizontal lines with symbol mark the median
and the interquartile range of the data is boxed. Significant reductions
in intensity (*) were observed for experiments 2 (EVida3; P,0.0001), 4
(E; P,0.0001), 5 (E; P=0.0002), 7 (EVida3; P,0.0001), 8 (EVida3;
P,0.0001). (B) Histograms show prevalence for strains E (white bars)
and EVida3 (grey bars) in experiments 1–8. Significant reductions (*)
were observed for experiments 2 (EVida3; P=0.01), 3 (EVida3; P=0.03)
and 4 (E; P=0.0003).
doi:10.1371/journal.pone.0014587.g005
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of pBluescript SK+. The carboxypeptidase promoter and SM1
tetramer from pBACAgCP[SM1]4 [14] were removed by NotI
digestion and cloned into pGEM-T to produce pGEM-
AgCP[SM1]4. This was digested with BamHI to replace [SM1]4
with the Vida3 tetramer cassette to produce pGEM-AgCP
[Vida3]4. The AgCP[Vida3]4 from pGEM-AgCP[Vida3]4 was
excised using NotI and cloned into the unique NotI site of the site-
specific integration plasmid pattB-DsRed2 [9]. Microinjection
DNA was prepared using the EndoFree Plasmid Maxi kit
(Qiagen). Oligonucleotide sequences are given in Table S3.
Transposase and integrase
phsp-pBac has been described previously [36]. All attB-attP
integrations used phiC31 integrase mRNA transcribed from
pET11phiC31poly(A) [11] using mMessage mMachine T7 Ultra
(Ambion) but omitting the DNase and poly(A) tailing steps. RNA
was purified (MegaClear, Ambion), precipitated and resuspended
in 10–15 ml of nuclease-free water.
Insect strains
An. gambiae (KIL) were maintained at 26uC61uC and 80% RH
in a 12-h light: 12-h dark photoperiod. Stock larvae were reared
under standardised conditions [37] and adults fed 10% glucose ad
libitum. Females (3–5 days old) were blood fed and preblastoderm
embryos collected for microinjection 48–96 hrs post-bloodmeal.
Surviving G0 males were backcrossed to wild-type in pools of 1–3
and females in pools of 5–10.
Microinjection
Microinjection was performed as previously reported [9]. For
phase 1, wild-type KIL strain embryos were co-injected with
pBac[3xP3-ECFPaf]-attP at 333 ng/ml and phsp-pBac [36] at
200 ng/ml in 1x injection buffer and recovered without heat shock.
For phase 2, strain E embryos were co-injected with pBattB-
DsRed2-AgCP-vida at 250 ng/ml and phiC31 mRNA at 800 to
1000 ng/ml. Surviving G0 adults were backcrossed to KIL and
putative G1 transformants identified by screening for fluorescence
(Leica MZ FLIII) with filter sets from Chroma Technology (ECFP:
exciter D436/20x; emitter D480/40m; DsRed: exciter HQ545/
30x; emitter HQ620/60m). Transgenic strains were established
from single G1 positive adults by backcrossing to wild-type (KIL
strain).
Infected bloodmeals
P. y. nigeriensis were maintained in CD1/S or TO male mice at
18uC +/2 2uC, with a 14:10 light:dark photoperiod. Mice were
initially infected with cryopreserved infected mouse blood,
followed by blood passage to synchronize the infection when
parasitaemia had reached approximately 10%. Infectivity was
estimated by the mean number of exflagellating microgametocytes
in 10 ml of mouse tail blood over 12 fields of view (x1000
magnification). Parasitaemia was assessed by Giemsa-stained thin
smears from tail blood. Test and control mosquitoes (3–5 days old;
glucose starved for 20 hrs) were fed simultaneously on the same
mouse, followed by removal of any females not fully engorged.
Mosquitoes were maintained on sugar cubes and distilled water
containing 0.05% PABA without an available oviposition site.
After 6–7 days, 50 midguts of each strain (when possible) were
dissected with oocysts and melanised ookinetes counted at 6400
magnification. Gametocytes of P. falciparum NF54 isolate were
produced by automated culture [38]. Details of culture conditions,
assessment of maturity and preparation for feeding are as
described in Mitri et al. [31]. Test and control mosquitoes (5 days
old; glucose starved) were left to feed in the dark for 15 minutes.
Fully engorged females were transferred to small cages with 10%
sucrose containing 0.05% PABA. A minimum of 30 midguts were
dissected after 8 days and stained with bromo-fluorescein to detect
oocysts.
Southern blotting
Genomic DNA was isolated using the Puregene DNA
Purification Kit (Gentra systems) from 10 headless mosquitoes,
crushed using Pellet Pestles (Anachem Ltd,), in a 5x modification
to the manufacturer’s Drosophila genomic purification protocol and
resuspended in a final volume of 50 ml. Approximately 10 mgo f
genomic DNA was digested with XmnI, NsiIo rPstI, separated on
1% agarose and blotted onto Hybond-N+ (Amersham Bioscienc-
es). The 2195 bp probe used to detect piggyBac integrations was
generated by EcoRV/PstI digestion of pBac[36P3-ECFPaf]-attP.
This fragment, containing 36P3-ECFP and a segment of the
piggyBac left terminus was labelled with [a-
32P]dCTP using Ready-
To-Go DNA labelling beads (Amersham Biosciences). Fragment
sizes were determined by comparison to the GeneRuler 1 kb DNA
ladder (Fermentas UK).
Inverse PCR
Inverse PCR was performed as described previously [9]. For
strains C, G and H, the 39 junctions were resolved using HaeIII
digestion together with primers 39FORnew with 39REVnew. For
strain E, the 59 junction sequence was obtained using TaqI
digestion and primers 59FOR with 59REV. To resolve 59 junctions
for strains C, G and H and the 39 junction for strain E, genomic
primers were designed to the An. gambiae PEST sequence using
primer select software (Lasergene, DNA Star). The relevant
primers for strains C, G, H and E respectively were C5geno-
micfwd, G5genomicfwd, H5genomicfwd and E5-3R-FWD. These
were used in conjunction with pBac PCR rev for 59 junctions or
39REVnew for the strain E 39 junction. PCR products were cloned
(pCR2.1-TOPO, Invitrogen) and sequenced (Lark Technologies).
Primer sequences are given in Table S3.
PCR analysis of site-specific integration
Unoccupied target sites were identified using primers to amplify
attP (attR-F-new with attL-R-new) and occupied sites were
identified using primers to amplify attL (attL-F-new-2 with attL-
R-new-2) and attR (attR-forward with attR-reverse). 250 ng
genomic DNA was amplified with the relevant primers (2 mM)
using Taq DNA polymerase (Sigma) in 1x buffer containing
1.5 mM MgCl2. Cycling parameters (MJ Research PTC-100)
were 94uC for 1 minute then 30 cycles (94uC, 30 seconds; 58uC,
30 seconds; 72uC, 30 seconds) followed by a final extension at
72uC for 10 minutes. PCR products were separated on 2%
agarose with HyperLadder IV (Bioline). PCR products were
cloned (pCR2.1-TOPO, Invitrogen) and sequenced (Lark Tech-
nologies). Primer sequences are given in Table S3.
RT-PCR
Female mosquitoes (3 days old) were membrane fed, collected
on ice at different times post-bloodmeal and frozen at 280uC.
Total RNA was extracted (TRIzol, Invitrogen) and 5 mg used for
reverse transcription (Superscript III, Invitrogen) with an oligo dT
primer. PCRs were performed with 10% of the RT reaction as
template. By limiting cycle numbers to the exponential phase (15
for rpL7a and 25 for Vida3) reactions were semi-quantitative and
band intensity could be quantified (Bio Imaging Systems, Syngene
Mosquito Anti-Malaria Gene
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AgCVIDArev were used to amplify the Vida3 sequence and
rpLfwd with rpLrev to amplify rpL7a control transcripts. PCRs
were performed using Taq DNA polymerase (1.5U, New England
BioLabs) and primers (0.5 mM, Proligo) and analysed on 1%
agarose gels. Cycling parameters were as described above except
that both reactions were annealed at 56uC and rpL7a reactions
were extended for 1 minute. Primer sequences are given in
Table S3.
Statistical analysis
Mendelian inheritance and parasite prevalence were analysed
by Chi-squared goodness of fit tests and wing lengths from 3
independent experiments were compared using a general linear
model (Minitab). Data sets for parasite intensity were not normally
distributed and were therefore analysed by Wilcoxon/Kruskal-
Wallis tests applied to pairwise comparisons between the different
groups of each experiment. Pooled data used a generalised linear
model with Poisson distribution and overdispersion parameter
(JMP7 software, e-academy Inc).
Ethics Statement
This study was carried out in strict accordance with UK Home
Office Guidelines as required by the Animals (Scientific Proce-
dures) Act 1986 under Project Licence PPL 40/2411 (Malaria-
Transmission by Mosquitoes). The protocol was approved by the
Keele University Animal Ethics Committee and all efforts were
made to minimize both the number of animals used and the
suffering caused.
Supporting Information
Figure S1 Parasite intensity following P. y. nigeriensis infections of
strains E and EVida3. Oocysts and melanised ookinetes are scored
as invading parasites in all experiments. Boxplots, of data from
Figure 4 on the same axes, show parasite intensity for strains E
(white boxes) and EVida3 (Grey boxes). Vertical lines denote the
95% confidence interval, horizontal lines with symbol mark the
median value and the box marks the interquartile range of the
data. Significant differences (*) for experiments are: 1, P=0.008; 2,
P=0.0007; 3, P=0.009; 4, P,0.0001; 5, P,0.0001 and pooled
data, P,0.0001.
Found at: doi:10.1371/journal.pone.0014587.s001 (0.28 MB TIF)
Table S1 Genomic DNA sequence analysis of attP integrations.
Table shows strain, chromosomal location (chromosome number
and arm followed by polytene map division and nucleotide
number of insertion) and flanking sequences 59 and 39 of the
piggyBac insert. All insertion sites are unique and have
characteristic TTAA sequence duplications either side of the
insert. The second insert site in strain C could not be resolved by
inverse PCR.
Found at: doi:10.1371/journal.pone.0014587.s002 (0.04 MB
DOC)
Table S2 Mendelian inheritance of fluorescent markers. Hemi-
zygous populations of strains E, G, H and EVida3 were crossed
inter-se and egg batches collected from individual females.
Approximately 100 F1 progeny, from a minimum of five egg
batches for each strain, were screened for fluorescence. All
individual F1 populations fitted the expected 3:1 phenotypic ratio
of fluorescence to wild-type. P.0.2 for all individual populations,
with P for pooled data shown above (n.s. - not significant).
Found at: doi:10.1371/journal.pone.0014587.s003 (0.03 MB
DOC)
Table S3 Oligonucleotides and primers. Oligonucleotides
VTET 1 FOR, VTET 1 REV, VTET 2 FOR and VTET 2
REV were annealed to form the Vida3 tetramer insert. Primers
39FORnew, 39REVnew, 59FOR and 59REV were used for inverse
PCR and C5genomicfwd, G5genomicfwd, H5genomicfwd, E5-
3R-FWD, pBac PCR rev and 39REVnew for genomic PCR.
Primers attR-F-new, attL-R-new, attL-F-new-2, attL-R-new-2,
attR-forward and attR-reverse were used in PCR reactions to
confirm site-specific integration. Primers AgCVIDAfwd with
AgCVIDArev or rpLfwd with rpLrev were used in RT-PCR.
Found at: doi:10.1371/journal.pone.0014587.s004 (0.05 MB
DOC)
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